Sort
21,453 grants matching “tuberculosis”
PS05-003 TUBERCULOSIS ELIMINATION AND LABORATORY
$2,395,293Mitchel Abramsky · Houston Department/Health/Human Srvs · U52 · FY2008 · PS
Case Clinical Trials Unit
$2,393,908Jeffrey M Jacobson · Case Western Reserve University · UM1 · FY2024 · AI
A Proteomics Research Center for Integrative Biology
$2,392,751Richard D Smith · Battelle Pacific Northwest Laboratories · P41 · FY2017 · GM
Optimization Of HIV Specific Immune Responses In Vivo
$2,392,577Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment
$2,391,540Alessandro Sette · La Jolla Institute For Immunology · U19 · FY2022 · AI
Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment
$2,391,540Alessandro Sette · La Jolla Institute For Immunology · U19 · FY2023 · AI
Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment
$2,391,540Alessandro Sette · La Jolla Institute For Immunology · U19 · FY2024 · AI
ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM FOR AIDS
$2,391,459University Of North Carolina Chapel Hill · U01 · FY2001 · AI
Structure-based Discovery of Critical Vulnerabilities of Mycobacteria
$2,387,567James C Sacchettini · Texas A&M Agrilife Research · P01 · FY2022 · AI
Immunopathogenic Mechanisms of Human Immunodeficiency Virus (HIV) Disease
$2,385,965Irini Sereti · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Botswana-Harvard School of Public Health AIDS Initiative Partnership CTU
$2,382,602Myron E Essex · Harvard School Of Public Health · UM1 · FY2014 · AI
Mali Project (Serefo)
$2,377,836Sophia Siddiqui · National Institute Of Allergy And Infectious Diseases · ZID · FY2009 · AI
A Proteomics Research Center for Integrative Biology
$2,374,818Richard D Smith · Battelle Pacific Northwest Laboratories · P41 · FY2013 · GM
International Epidemiologic Databases to Evaluate AIDS-Southern Africa (IeDEA-SA)
$2,370,132Matthias Egger · Universitat Bern · U01 · FY2011 · AI
The UCSD CD4 Collaborative Clinical Trial Unit
$2,370,023Constance Ann Benson · University Of California, San Diego · UM1 · FY2017 · AI
PERU Clinical Trial Unit
$2,365,819Jorge Luis Sanchez · Asociacion Civil Impacta Salud Y Educacn · UM1 · FY2023 · AI
Immunopathogenic Mechanisms of Human Immunodeficiency Virus (HIV) Disease
$2,365,134Irini Sereti · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Pathway Analysis in Tuberculosis
$2,363,433Sabine Ehrt · Weill Medical Coll Of Cornell Univ · P01 · FY2023 · AI
Resources and workforce development for the New England Regional Biosafety Laboratory
$2,363,198Sam R. Telford · Tufts University Boston · UC7 · FY2025 · AI
Discovery of Chemical Probes and Therapeutic Leads, Phase II
$2,359,432Joseph M Fox · University Of Delaware · P20 · FY2021 · GM
Discovery of Chemical Probes and Therapeutic Leads, Phase II
$2,359,432Joseph M Fox · University Of Delaware · P20 · FY2022 · GM
Modulating Eicosanoids to Treat Tuberculosis: Personalized, Host-directed Therapy
$2,355,000David M. Tobin · Duke University · DP2 · FY2011 · OD
Efflux pump inhibitors to reduce duration of antituberculosis therapy
$2,355,000Tawanda Gumbo · Ut Southwestern Medical Center · DP2 · FY2007 · OD
IMPACTA PERU CLINICAL TRIALS UNIT
$2,354,219Jorge Luis Sanchez · Asociacion Civil Impacta Salud Y Educacn · UM1 · FY2014 · AI
New approaches to optimizing the application and measuring the impact of community-based tuberculosis interventions
$2,353,629Courtney M. Yuen · Brigham And Women'S Hospital · DP2 · FY2019 · MD